Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes

This study has been completed.
Information provided by:
University Hospital, Gentofte, Copenhagen Identifier:
First received: May 2, 2006
Last updated: June 23, 2015
Last verified: September 2008
Results First Received: September 29, 2008  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Diagnostic
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Sulfonylurea

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
May 2006 - March 2007, Outpatient clinic and advertisement

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Sulfonylurea No text entered.

Participant Flow:   Overall Study
STARTED     12  
COMPLETED     12  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Sulfonylurea No text entered.

Baseline Measures
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     11  
>=65 years     1  
[units: years]
Mean (Standard Deviation)
  55  (7.6)  
[units: participants]
Female     4  
Male     8  
Region of Enrollment  
[units: participants]
Denmark     12  

  Outcome Measures

1.  Primary:   Insulin Secretion   [ Time Frame: 0 - 90 minutes ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

  More Information